Drug updated on 11/15/2023

Dosage FormTablet (oral: 4.5 mg, 9 mg, 13.5 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies


  • For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
  • For the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.

Product Monograph / Prescribing Information

Document TitleYearSource
Pemazyre (pemigatinib) Prescribing Information.2023Incyte Corporation, Wilmington, DE

Systematic Reviews / Meta-Analyses